Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy
Since radical prostatectomy is performed to cure prostate cancer, identification of markers enabling preoperative prediction of relapse after radical prostatectomy is essential to counsel and select patients for adjuvant therapy. Aberrant p53, bcl-2, CD44 and E-cadherin immunohistochemistry has been...
Uložené v:
| Vydané v: | The Journal of urology Ročník 161; číslo 4; s. 1238 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.04.1999
|
| Predmet: | |
| ISSN: | 0022-5347 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Since radical prostatectomy is performed to cure prostate cancer, identification of markers enabling preoperative prediction of relapse after radical prostatectomy is essential to counsel and select patients for adjuvant therapy. Aberrant p53, bcl-2, CD44 and E-cadherin immunohistochemistry has been associated with aggressiveness in prostate cancer. We assessed these biomarkers in biopsy and radical prostatectomy specimens as predictors of biochemical relapse.
A total of 76 patients with untreated clinically localized prostatic adenocarcinoma underwent radical prostatectomy. Preoperative (prostate specific antigen, biopsy Gleason score) and postoperative (pathological stage and margin status) variables, biopsy and radical prostatectomy biomarker immunohistochemistry were correlated with relapse. Univariate and multivariate statistical analyses identified significant predictors.
Of the 76 patients 23 (30%) had relapse (mean followup 38 months). Aberrant p53, bcl-2, CD44 and E-cadherin expression was observed in 64, 12, 85 and 12% of biopsies and 57, 20, 64 and 49% of radical prostatectomy specimens, respectively. Biopsy Gleason 7 to 10 and biopsy p53, respectively, gave the highest positive and negative predictive values for relapse. Relapse occurred in 13% of patients with normal biopsy p53 and in half with aberrant p53. Multivariate analysis revealed Gleason score and p53 to be independent preoperative predictors (p = 0.01 and 0.02, respectively). Estimated risk of relapse was 3.5 times higher in patients with Gleason scores 7 to 10 and 24% higher in those with aberrant p53. Significant postoperative predictors were bcl-2, p53, Gleason score and margin status (p = 0.01, 0.01, 0.04 and 0.01, respectively).
Aberrant biopsy p53 is associated with a significantly worse outcome after radical prostatectomy than normal p53, highlighting a potential clinical role for p53. Postoperative p53 and bcl-2 were significant predictors of outcome after radical prostatectomy. |
|---|---|
| AbstractList | Since radical prostatectomy is performed to cure prostate cancer, identification of markers enabling preoperative prediction of relapse after radical prostatectomy is essential to counsel and select patients for adjuvant therapy. Aberrant p53, bcl-2, CD44 and E-cadherin immunohistochemistry has been associated with aggressiveness in prostate cancer. We assessed these biomarkers in biopsy and radical prostatectomy specimens as predictors of biochemical relapse.
A total of 76 patients with untreated clinically localized prostatic adenocarcinoma underwent radical prostatectomy. Preoperative (prostate specific antigen, biopsy Gleason score) and postoperative (pathological stage and margin status) variables, biopsy and radical prostatectomy biomarker immunohistochemistry were correlated with relapse. Univariate and multivariate statistical analyses identified significant predictors.
Of the 76 patients 23 (30%) had relapse (mean followup 38 months). Aberrant p53, bcl-2, CD44 and E-cadherin expression was observed in 64, 12, 85 and 12% of biopsies and 57, 20, 64 and 49% of radical prostatectomy specimens, respectively. Biopsy Gleason 7 to 10 and biopsy p53, respectively, gave the highest positive and negative predictive values for relapse. Relapse occurred in 13% of patients with normal biopsy p53 and in half with aberrant p53. Multivariate analysis revealed Gleason score and p53 to be independent preoperative predictors (p = 0.01 and 0.02, respectively). Estimated risk of relapse was 3.5 times higher in patients with Gleason scores 7 to 10 and 24% higher in those with aberrant p53. Significant postoperative predictors were bcl-2, p53, Gleason score and margin status (p = 0.01, 0.01, 0.04 and 0.01, respectively).
Aberrant biopsy p53 is associated with a significantly worse outcome after radical prostatectomy than normal p53, highlighting a potential clinical role for p53. Postoperative p53 and bcl-2 were significant predictors of outcome after radical prostatectomy. Since radical prostatectomy is performed to cure prostate cancer, identification of markers enabling preoperative prediction of relapse after radical prostatectomy is essential to counsel and select patients for adjuvant therapy. Aberrant p53, bcl-2, CD44 and E-cadherin immunohistochemistry has been associated with aggressiveness in prostate cancer. We assessed these biomarkers in biopsy and radical prostatectomy specimens as predictors of biochemical relapse.PURPOSESince radical prostatectomy is performed to cure prostate cancer, identification of markers enabling preoperative prediction of relapse after radical prostatectomy is essential to counsel and select patients for adjuvant therapy. Aberrant p53, bcl-2, CD44 and E-cadherin immunohistochemistry has been associated with aggressiveness in prostate cancer. We assessed these biomarkers in biopsy and radical prostatectomy specimens as predictors of biochemical relapse.A total of 76 patients with untreated clinically localized prostatic adenocarcinoma underwent radical prostatectomy. Preoperative (prostate specific antigen, biopsy Gleason score) and postoperative (pathological stage and margin status) variables, biopsy and radical prostatectomy biomarker immunohistochemistry were correlated with relapse. Univariate and multivariate statistical analyses identified significant predictors.MATERIALS AND METHODSA total of 76 patients with untreated clinically localized prostatic adenocarcinoma underwent radical prostatectomy. Preoperative (prostate specific antigen, biopsy Gleason score) and postoperative (pathological stage and margin status) variables, biopsy and radical prostatectomy biomarker immunohistochemistry were correlated with relapse. Univariate and multivariate statistical analyses identified significant predictors.Of the 76 patients 23 (30%) had relapse (mean followup 38 months). Aberrant p53, bcl-2, CD44 and E-cadherin expression was observed in 64, 12, 85 and 12% of biopsies and 57, 20, 64 and 49% of radical prostatectomy specimens, respectively. Biopsy Gleason 7 to 10 and biopsy p53, respectively, gave the highest positive and negative predictive values for relapse. Relapse occurred in 13% of patients with normal biopsy p53 and in half with aberrant p53. Multivariate analysis revealed Gleason score and p53 to be independent preoperative predictors (p = 0.01 and 0.02, respectively). Estimated risk of relapse was 3.5 times higher in patients with Gleason scores 7 to 10 and 24% higher in those with aberrant p53. Significant postoperative predictors were bcl-2, p53, Gleason score and margin status (p = 0.01, 0.01, 0.04 and 0.01, respectively).RESULTSOf the 76 patients 23 (30%) had relapse (mean followup 38 months). Aberrant p53, bcl-2, CD44 and E-cadherin expression was observed in 64, 12, 85 and 12% of biopsies and 57, 20, 64 and 49% of radical prostatectomy specimens, respectively. Biopsy Gleason 7 to 10 and biopsy p53, respectively, gave the highest positive and negative predictive values for relapse. Relapse occurred in 13% of patients with normal biopsy p53 and in half with aberrant p53. Multivariate analysis revealed Gleason score and p53 to be independent preoperative predictors (p = 0.01 and 0.02, respectively). Estimated risk of relapse was 3.5 times higher in patients with Gleason scores 7 to 10 and 24% higher in those with aberrant p53. Significant postoperative predictors were bcl-2, p53, Gleason score and margin status (p = 0.01, 0.01, 0.04 and 0.01, respectively).Aberrant biopsy p53 is associated with a significantly worse outcome after radical prostatectomy than normal p53, highlighting a potential clinical role for p53. Postoperative p53 and bcl-2 were significant predictors of outcome after radical prostatectomy.CONCLUSIONSAberrant biopsy p53 is associated with a significantly worse outcome after radical prostatectomy than normal p53, highlighting a potential clinical role for p53. Postoperative p53 and bcl-2 were significant predictors of outcome after radical prostatectomy. |
| Author | Trivella, M Abbott, C D Oxley, J D Brewster, S F Gillatt, D A |
| Author_xml | – sequence: 1 givenname: S F surname: Brewster fullname: Brewster, S F organization: Bristol Urological Institute, Department of Cellular Pathology, Southmead Hospital, University of Bristol, United Kingdom – sequence: 2 givenname: J D surname: Oxley fullname: Oxley, J D – sequence: 3 givenname: M surname: Trivella fullname: Trivella, M – sequence: 4 givenname: C D surname: Abbott fullname: Abbott, C D – sequence: 5 givenname: D A surname: Gillatt fullname: Gillatt, D A |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/10081877$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kEtLxDAUhbMYcR76E5SsRGGqeTRJs5RxfMCAggruSpreMpW2qUkqzNZfbtHR1YFzv3sv58zRpHMdIHRCySUlVF49E8JYIniqzgm9kFSmMnmboNm_PUXzEN4JoalQ7BBNKSEZzZSaoa8nD64Hb2L9CbgXfIkL2yRsiVc3aYpNV-J1Yk25BV93uG7boXPbOkRnt9CO6nfYBNx7KGsbnQ_YVbiof6fWNNhDY_oA2FQRPPam_HF770I0EcaVdneEDirTBDje6wK93q5fVvfJ5vHuYXW9SSzXJCbWaltZJo2lXGaikJIrWbFUCJoBF6zQGdVkDMWFVVpzbjmnGrQyJR_xlC3Q2e_d8fvHACHmYwALTWM6cEPIpZZMccVG8HQPDkULZd77ujV-l_-1xr4BLdRv1Q |
| CitedBy_id | crossref_primary_10_1016_j_cancergencyto_2007_08_017 crossref_primary_10_1371_journal_pone_0082625 crossref_primary_10_5858_arpa_2011_0471_RA crossref_primary_10_3816_CGC_2002_n_006 crossref_primary_10_1016_j_juro_2006_07_133 crossref_primary_10_1093_jnci_95_9_661 crossref_primary_10_1038_sj_onc_1207920 crossref_primary_10_1016_j_eursup_2017_10_001 crossref_primary_10_1016_S0094_0143_05_70164_6 crossref_primary_10_1007_s00345_008_0260_5 crossref_primary_10_1016_j_critrevonc_2009_02_007 crossref_primary_10_1016_j_juro_2006_06_014 crossref_primary_10_1097_PAP_0b013e3182863f80 crossref_primary_10_1002_path_1084 crossref_primary_10_1002_pros_21504 crossref_primary_10_1016_S1078_1439_00_00119_8 crossref_primary_10_1016_S0022_5347_05_65953_8 crossref_primary_10_1002_cjp2_61 crossref_primary_10_1097_01_pai_0000210417_61117_6c crossref_primary_10_1177_107327480100800612 crossref_primary_10_1002_cncr_11230 crossref_primary_10_1038_aja_2008_22 crossref_primary_10_1016_S0094_0143_05_70155_5 crossref_primary_10_5507_bp_2003_001 crossref_primary_10_1016_S0210_4806_07_73765_8 crossref_primary_10_1097_PAI_0000000000000015 crossref_primary_10_1097_00005392_200009010_00023 crossref_primary_10_1046_j_1464_410X_2002_02541_x crossref_primary_10_1111_j_1349_7006_2002_tb01219_x crossref_primary_10_1002_pros_20222 crossref_primary_10_1016_j_humpath_2010_07_007 crossref_primary_10_1046_j_1464_410x_2000_00787_x crossref_primary_10_1016_j_ejca_2004_12_035 crossref_primary_10_1007_s00432_012_1351_7 crossref_primary_10_1097_00005392_200012000_00028 crossref_primary_10_1177_1756287214545328 crossref_primary_10_1016_S0090_4295_00_00903_1 crossref_primary_10_1080_00313020310001619163 crossref_primary_10_1155_2011_290160 crossref_primary_10_1016_S0210_4806_99_72380_6 crossref_primary_10_1016_S0022_5347_05_66934_0 crossref_primary_10_1097_00001622_200005000_00014 crossref_primary_10_5858_2010_0727_RAIR_1 crossref_primary_10_1016_j_critrevonc_2006_07_003 crossref_primary_10_1080_00313020220131282 crossref_primary_10_3390_medicina60122032 crossref_primary_10_1586_14737159_2014_936851 crossref_primary_10_1111_j_1600_0463_2008_0s123_x crossref_primary_10_1016_j_urology_2003_10_007 crossref_primary_10_1016_S0090_4295_03_00264_4 crossref_primary_10_1101_gad_819500 crossref_primary_10_1016_j_urolonc_2007_01_022 crossref_primary_10_1097_PAI_0b013e3181640bca crossref_primary_10_1016_S0959_8049_01_00143_5 crossref_primary_10_1002_path_1791 crossref_primary_10_1016_S0022_5347_05_68096_2 crossref_primary_10_1002_cncr_27597 crossref_primary_10_3390_jpm13050870 crossref_primary_10_1007_s12253_011_9435_2 crossref_primary_10_1016_j_suronc_2005_05_003 crossref_primary_10_1016_j_urolonc_2006_07_004 crossref_primary_10_1016_S0022_5347_05_67288_6 crossref_primary_10_1155_2018_2061268 crossref_primary_10_1046_j_1464_410x_2000_00916_x crossref_primary_10_1371_journal_pone_0003949 crossref_primary_10_3109_00313021003779145 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/S0022-5347(01)61646-X |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 10081877 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K .55 .GJ .XZ 08P 0R~ 123 1B1 1CY 354 3O- 4.4 457 4G. 4Q1 4Q2 4Q3 53G 5RE 5VS 7-5 AAAAV AAEDT AAEDW AAGIX AAHPQ AAIQE AAJCS AAKAS AALRI AAMOA AAQFI AAQKA AAQQT AAQXK AASCR AASXQ AAXUO ABASU ABCQX ABDIG ABJNI ABLJU ABMAC ABOCM ABPPZ ABVCZ ABWVN ACGFS ACIJW ACILI ACLDA ACOAL ACRPL ACXJB ADGGA ADHPY ADMUD ADNKB ADNMO ADPAM ADZCM AEBDS AEETU AENEX AFDTB AFEXH AFFNX AFTRI AFUWQ AGHFR AHOMT AHQNM AHRYX AHVBC AI. AINUH AITUG AIZYK AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AMRAJ ASGHL ASPBG AVWKF AZFZN BCGUY BELOY BYPQX C45 C5W CGR CS3 CUY CVF DIWNM DU5 EBS ECM EEVPB EIF EJD ERAAH EX3 F5P FCALG FDB FEDTE FGOYB GBLVA GNXGY GQDEL HLJTE HVGLF HZ~ H~9 IH2 IHE IKREB IKYAY IPNFZ J5H KMI L7B M41 MJL MO0 N4W NPM NQ- NTWIH O9- OAG OAH OB3 OBH ODMTH OGROG OHH OL1 OVD OWU OWV OWW OWY OWZ P2P PKN QTD R2- RIG RLZ ROL RPZ SEL SES SJN SSZ TEORI TSPGW UDS UNMZH UV1 VH1 VVN WOW X7M XH2 XYM YFH YOC ZCG ZFV ZGI ZXP ZY1 ZZMQN 7X8 ABPXF ACVFH ADCNI AGQPQ |
| ID | FETCH-LOGICAL-c390t-cc9cfc26ac13685b66376f245518e352b9819087735c79933c3319e97ad385b42 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 87 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000079014000057&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0022-5347 |
| IngestDate | Fri Jul 11 16:22:10 EDT 2025 Wed Feb 19 01:20:47 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c390t-cc9cfc26ac13685b66376f245518e352b9819087735c79933c3319e97ad385b42 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 10081877 |
| PQID | 69627372 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_69627372 pubmed_primary_10081877 |
| PublicationCentury | 1900 |
| PublicationDate | 1999-04-01 |
| PublicationDateYYYYMMDD | 1999-04-01 |
| PublicationDate_xml | – month: 04 year: 1999 text: 1999-04-01 day: 01 |
| PublicationDecade | 1990 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | The Journal of urology |
| PublicationTitleAlternate | J Urol |
| PublicationYear | 1999 |
| SSID | ssj0014572 |
| Score | 1.9187306 |
| Snippet | Since radical prostatectomy is performed to cure prostate cancer, identification of markers enabling preoperative prediction of relapse after radical... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1238 |
| SubjectTerms | Aged Cadherins - analysis Genes, bcl-2 Humans Hyaluronan Receptors - analysis Immunohistochemistry Male Middle Aged Neoplasm Recurrence, Local - chemistry Neoplasm Recurrence, Local - mortality Postoperative Care Predictive Value of Tests Preoperative Care Prostatectomy Prostatic Neoplasms - chemistry Prostatic Neoplasms - mortality Prostatic Neoplasms - surgery Proto-Oncogene Proteins c-bcl-2 - analysis Risk Factors Survival Rate Tumor Suppressor Protein p53 - analysis |
| Title | Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/10081877 https://www.proquest.com/docview/69627372 |
| Volume | 161 |
| WOSCitedRecordID | wos000079014000057&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT4MwGG6mM8aL3x_zswcPmqwRKNCSmBgzt3jZsoMm3JbyUpIlCgjTxKu_3L58uJPx4IUDtATat-Upb5_nIeRS2lxLH1zmxxKYK8EMKbA4ixVY2rZ0JKE2mxCTiQzDYNohty0XBrdVtnNiNVHHGeA_8hsfXWK4cO7yN4aeUZhbbQw0VkiXGyCDMS3CZQ7B9cSPVrjHXbHk7yA_uDl5ZdnXPmpssfB3jFl9a0Zb_3vKbbLZYEx6XwfFDunodJesj5ss-h75mhY6y3Wt-U1zj_dpBC_M6dPBg-tSlcZ0yEDFFTWQzpFBklW6xNC6w1FV0rzAG6JZD80SGs3rq6bLKfJj8lLTyn-cFqpKBZnyWcVeMlVeP_fJ82j4NHhkjRcDAx5YCwYQQAKOr8BGyfrIABXhJ46Lgm7agLgoQGghheAeCIN5OHAzuHUgVMxNcdc5IKtpluojQmMhk0hIbakoQK-TAKQfRJYyCymzdrKdHrlo23ZmXgoTGCrV2Xs5a1u3Rw7r7pnltSQHKi8b5CHE8Z91T8hGrbyAm29OSTcxo1yfkTX4WMzL4rwKIXOcTMff2ZbPbw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Preoperative+p53%2C+bcl-2%2C+CD44+and+E-cadherin+immunohistochemistry+as+predictors+of+biochemical+relapse+after+radical+prostatectomy&rft.jtitle=The+Journal+of+urology&rft.au=Brewster%2C+S+F&rft.au=Oxley%2C+J+D&rft.au=Trivella%2C+M&rft.au=Abbott%2C+C+D&rft.date=1999-04-01&rft.issn=0022-5347&rft.volume=161&rft.issue=4&rft.spage=1238&rft_id=info:doi/10.1016%2FS0022-5347%2801%2961646-X&rft_id=info%3Apmid%2F10081877&rft_id=info%3Apmid%2F10081877&rft.externalDocID=10081877 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-5347&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-5347&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-5347&client=summon |